Patients with prodromal Parkinson disease (PD) are most likely to respond to disease-modifying strategies. To date, cognitive impairment has been viewed as a complication of late-stage disease, but a longitudinal analysis of data from the Rotterdam cohort raises the possibility that such impairments are also associated with prodromal PD.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Aarsland, D. et al. Cognitive decline in Parkinson disease. Nat. Rev. Neurol. 13, 217–231 (2017).
Berg, D. et al. MDS research criteria for prodromal Parkinson's disease. Mov. Disord. 30, 1600–1611 (2015).
Athauda, D. & Foltynie, T. Challenges in detecting disease modification in Parkinson's disease clinical trials. Parkinsonism Relat. Disord. 32, 1–11 (2016).
Darweesh, S. K. L. et al. Association between poor cognitive functioning and risk of incident parkinsonism: the Rotterdam study. JAMA Neurol. http://dx.doi.org/10.1001/jamaneurol.2017.2248 (2017).
Iranzo, A. et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 9, 1070–1077 (2010).
Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. 24, 197–211 (2003).
Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov. Disord. 30, 1591–1601 (2015).
Compta, Y. et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 134, 1493–1505 (2011).
Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol. 95, 629–635 (2011).
Noyce, A. J. et al. PREDICT-PD: identifying risk of Parkinson's disease in the community: methods and baseline results. J. Neurol. Neurosurg. Psychiatry 85, 31–37 (2014).
Acknowledgements
Y.C. and M.J.M. gratefully acknowledge financial support from the CERCA Programme of the Generalitat de Catalunya (Barcelona, Catalonia, Spain).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Compta, Y., Martí, M. What goes around comes around: cognitive impairment as prodromal parkinsonism?. Nat Rev Neurol 13, 709–710 (2017). https://doi.org/10.1038/nrneurol.2017.159
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2017.159